Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.
Download the Novartis pipeline as of December 31, 2022 (PDF 0.1 MB)
- AAA601Lutathera®Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3 tumors (GEP-NET 1L G3)Solid Tumors Phase 3 2023 Radioligand therapy target SSTRSupplementary Indication
- AAA601Lutathera®GEPNET, pediatricsSolid Tumors Phase 2 Radioligand therapy target SSTR
- AAA601Lutathera®GlioblastomaSolid Tumors Phase 2 Radioligand therapy target SSTR
- AAA601Lutathera®1L ES-SCLCSolid Tumors Phase 2 Radioligand therapy target SSTR
- AAA603177Lu-NeoBMultiple solid tumorsSolid Tumors Phase 1 >=2026 Radioligand therapy target GRPRLead Indication
- AAA617Pluvicto®Metastatic hormone sensitive prostate cancer (mHSPC)Solid Tumors Phase 3 2024 Radioligand therapy target PSMANew Indication
- AAA617Pluvicto®Metastatic castration-resistant prostate cancer (mCRPC) pre-taxaneSolid Tumors Phase 3 2023 Radioligand therapy target PSMANew Indication
- AAA817225Ac-PSMA-617Metastatic castration-resistant prostate cancerSolid Tumors Phase 1 Radioligand therapy target PSMALead Indication
- ABL001Scemblix®Chronic myeloid leukemia, 1st lineHematology Phase 3 2025 BCR-ABL inhibitorNew Indication
- ABL001Scemblix®Chronic myeloid leukemia, 2L, pediatricsHematology Phase 2 >=2026 BCR-ABL inhibitorNew Indication
- AIN457Cosentyx®Polymyalgia rheumaticaImmunology Phase 3 >=2026 IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)
- AIN457Cosentyx®Rotator cuff tendinopathyImmunology Phase 3 >=2026 IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)
- AIN457Cosentyx®Lupus NephritisImmunology Phase 3 >=2026 IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)Supplementary Indication
- AIN457Cosentyx®Giant cell arteritis (GCA)Immunology Phase 3 2025 IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)Supplementary Indication
- AIN457Cosentyx®Hidradenitis suppurativaImmunology Registration IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)Supplementary Indication
- AIN457Cosentyx®Psoriatic arthritis (IV formulation)Immunology Registration IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)Supplementary Indication
- AIN457Cosentyx®Axial SpA (IV formulation)Immunology Registration IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)Supplementary Indication
- AMG334Aimovig®Migraine, pediatricsNeuroscience Phase 3 >=2026 Selective CGRP receptor antagonistSupplementary Indication
- BAF312Mayzent®Multiple sclerosis, pediatricsNeuroscience Phase 3 >=2026 S1P1 Modulator (Sphingosine-1-phosphate receptor modulator)Supplementary Indication
- BLZ945sotuletinibAmyotrophic lateral sclerosis (ALS)Neuroscience Phase 2 CSF-1R inhibitorLead Indication
NSAI Non-steroidal aromatase inhibitor
Taf Tafinlar® (dabrafenib)
Mek Mekinist® (trametinib)
a EU filing, approved in US.
b US filing, approved in EU.
c US filing, submitted in EU.
d US pending submission, approved in EU
e EU filing, submitted in US.
This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.
In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.